Načítá se...
Long-term Survival of Locally Advanced Stage III Non-small Cell Lung Cancer Patients Treated with Chemoradiotherapy and Perspectives for The Treatment with Immunotherapy
BACKGROUND: Standard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported. PATIENTS AND METHODS: A total of 102 p...
Uloženo v:
| Vydáno v: | Radiol Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Sciendo
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6137367/ https://ncbi.nlm.nih.gov/pubmed/30210037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/raon-2018-0009 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|